

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

BSE Limited 1 st Floor, P.J. Towers Dalal Street Mumbai – 400 001 Kind Attn.: Mr. Sanjay Golecha / Mr. Gopalkrishnan	National Stock Exchange of India Limited Exchange Plaza, 5 th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) Mumbai – 400 051 Kind Attn.: Famroze Pochara Asst. Vice President
Date: March 29, 2016	
Re.: Press Release.	


Dear Sir / Madam,


We enclose herewith a copy of press release dated March 29, 2016 under the title “**Zydus receives final approval from the USFDA for Acyclovir Capsules USP to be produced at the formulations manufacturing facility at SEZ, Ahmedabad**”. The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,
For Cadila Healthcare Limited


Upen H. Shah
Company Secretary



Encl.: As above.

Zydus receives final approval from the USFDA for Acyclovir Capsules USP

The formulations manufacturing facility at SEZ will produce the drug for the US market

Ahmedabad, 29 March 2016

Zydus Cadila has received the final approval from the USFDA to market Acyclovir Capsules USP, 200 mg. The drug falls in the anti-viral segment and will be produced at the formulations manufacturing facility at SEZ, Ahmedabad.

The group now has more than 100 approvals and has so far filed over 280 ANDAs since the commencement of the filing process in FY 2003-04.
